OKYO Pharma will participate in the Cantor Global Healthcare Conference on September 9-11, 2026, including a fireside chat and one-on-one meetings. The investor-facing appearance follows positive FDA Type D meeting feedback on urcosimod’s regulatory and clinical path and a strengthened cash position in its annual report.
Key Highlights
- Flavio Mantelli and Gary Jacob will represent OKYO Pharma at the conference.
- OKYO Pharma linked its participation to positive feedback from a U.S. FDA Type D meeting.
- OKYO Pharma will participate in the Cantor Global Healthcare Conference.
- A fireside chat is scheduled for September 10, 2026.
OKYO Pharma Ltd (NASDAQ: OKYO) will participate in the Cantor Global Healthcare Conference, with a fireside chat scheduled for September 10, 2026. The clinical-stage biopharmaceutical company is developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases.
Cantor Conference Features OKYO Executives
The conference is being held September 9-11, 2026. Chief Medical Officer Flavio Mantelli, MD, PhD, and Chief Development Officer Gary Jacob, PhD, will represent OKYO Pharma in the discussion. Eric Fitzgerald of Cantor Fitzgerald will moderate the session. The company’s ordinary shares are listed on the Nasdaq Capital Market.
FDA Feedback Supports Urcosimod Path
OKYO Pharma said its conference presence follows positive feedback from a U.S. Food and Drug Administration Type D meeting. The feedback validated the regulatory and clinical path forward for urcosimod. The company also pointed to its annual report, which reflected a strengthened cash position. OKYO Pharma describes its development work as focused on neuropathic corneal pain and anterior segment eye diseases. Its activities include investigational therapies in those areas.
FAQs
Q: When is OKYO Pharma’s Cantor Global Healthcare Conference appearance?
A: OKYO Pharma is participating in the Cantor Global Healthcare Conference being held September 9-11, 2026. Its fireside chat is scheduled for September 10, 2026.
Q: What will OKYO Pharma discuss at the conference?
A: Flavio Mantelli and Gary Jacob will represent OKYO Pharma in the conference discussion. Eric Fitzgerald of Cantor Fitzgerald will moderate the fireside chat.
Q: Why are investors watching OKYO Pharma’s conference participation?
A: The appearance follows positive U.S. FDA Type D meeting feedback validating urcosimod’s regulatory and clinical path. OKYO Pharma also cited a strengthened cash position in its annual report.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.